Prostate cancer is a major cause of cancer morbidity and mortality. Intra-prostatic
inflammation is a risk factor for prostate carcinogenesis, with diet, chemical injury and an …

Progress in cancer treatment has improved the survival of patients with advanced-stage
cancers. Consequently, the clinical courses of patients are prolonged and often …

Purpose: Pelvic lymph node dissection represents the gold standard of lymph node staging
in patients with prostate cancer. We sought to assess the effect of extended pelvic lymph …

Despite significant advances in therapeutic developments for prostate cancer over the last 2
decades, metastatic prostate cancer remains a lethal disease. Prostate-specific membrane …

Background In 2004, docetaxel was shown to prolong the overall survival (OS) of patients
with metastatic castration-resistance prostate cancer (mCRPC). Since 2010, five new …

Prostate cancer is the most common type of cancer and the leading cause of cancer deaths
among men in many countries. Preventing progression is a major concern for prostate …

Objectives To quantify the magnitude of differences between observed overall survival and
respective, age‐adjusted Social Security Administration life tables‐derived life expectancy in …

Purpose To quantify the prognostic effect of the location of prostate cancer (PCa) metastases
on cancer-specific mortality (CSM) and the rate of other-cause mortality (OCM) in …

Background During the past two decades, new antitumor drugs (Abiraterone, Enzalutamide,
Radium-223, Cabazitaxel, and Docetaxel) have been introduced for treatment of prostate …

Introduction The number of patients with metastatic castration-resistant prostate cancer
(mCRPC) is expected to increase due to the long life expectancy of those with advanced …